Spectrums of Amyotrophic Lateral Sclerosis Heterogeneity Pathogenesis and Therapeutic Directions 1st Edition by John Wiley, Sons PT 9781119745518 1119745519

Spectrums of Amyotrophic Lateral Sclerosis Heterogeneity Pathogenesis and Therapeutic Directions 1st Edition  by John Wiley, Sons PT – Ebook PDF Instant Download/Delivery: 9781119745518, 1119745519

Full download Spectrums of Amyotrophic Lateral Sclerosis Heterogeneity Pathogenesis and Therapeutic Directions 1st Edition after payment

Product details:

• ISBN 10:1119745519 

• ISBN 13:9781119745518

• Author:John Wiley, Sons PT 

 Spectrums of Amyotrophic Lateral Sclerosis: Heterogeneity, Pathogenesis and Therapeutic Directions
Heterogeneity, Pathogenesis and Therapeutic Directions
SPECTRUMS OF AMYOTROPHIC LATERAL SCLEROSIS Discover state-of-the-art research findings on ALS from leading authors and editors in the field In Spectrums of Amyotrophic Lateral Sclerosis: Heterogeneity, Pathogenesis & Therapeutic Directions, distinguished researchers and editors Dr. Christopher A. Shaw and Jessica R. Morrice deliver a practical and powerful perspective on Amyotrophic Lateral Sclerosis (ALS) as a heterogeneous spectrum of disorders. This increasingly accepted point-of-view allows researchers and medical professionals to develop better targeted interventions and more precise therapies. In the book, readers will find chapters on a wide variety of critical issues facing ALS researchers and healthcare practitioners treating ALS sufferers, including animal models of ALS, neuronal support cells known to have a pivotal role in ALS, and current challenges in ALS clinical trials, among others. The authors describe pathologic features common to all cases of ALS and why animal models, though crucial, should be interpreted with caution. Finally, multiple genetic and environmental etiologies of the disease are discussed. Readers will also benefit from the inclusion of: A thorough introduction to ALS as a spectrum disease and the implications for models, therapeutic development and clinical trial design Explorations of the genetic basis of ALS, prospective sALS etiologies, and the involvement of microbiome in ALS Discussions of ALS-PDC and environmental risk factors, protein aggregation in ALS, defects in RNA metabolism in ALS, and the non-cell autonomous nature of ALS and the involvement of glial cells Examinations of animal models of ALS and perspectives on previously failed ALS therapeutics and current therapeutic strategies Perfect for clinical neurologists, healthcare providers and caretakers, clinicians, and researchers studying motor neuron disease, Spectrums of Amyotrophic Lateral Sclerosis: Heterogeneity, Pathogenesis & Therapeutic Directions is also an indispensable resource for the neurodegenerative research community, neurology residents, and graduate-level neuroscience students.

Spectrums of Amyotrophic Lateral Sclerosis Heterogeneity Pathogenesis and Therapeutic Directions 1st Table of contents:

 CHAPTER 1: Clinical Heterogeneity of ALS – Implications for Models and Therapeutic Development
INTRODUCTION
CLINICAL HETEROGENEITY OF ALS
PLEIOTROPY OF ALS GENES
GENETIC MODELS TO STUDY ALS
CONCLUSION
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 2: Genetic Basis of ALS
INTRODUCTION
GENES CAUSING ALS
RECENTLY DISCOVERED GENES
ASPECTS OF ALS HERITABILITY
NONCODING VARIATION
CONCLUSIONS
ACKNOWLEDGMENTS
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 3: Susceptibility Genes and Epigenetics in Sporadic ALS
INTRODUCTION
ENVIRONMENTAL ASSOCIATIONS IN sALS
GENETIC BASIS OF sALS
IDENTIFICATION OF sALS SUSCEPTIBILITY GENES
CANDIDATE sALS SUSCEPTIBILITY GENES
EPIGENETIC MECHANISMS IN sALS
MODIFICATIONS TO THE EPIGENOME BY ENVIRONMENTAL FACTORS
CONCLUSION
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 4: The Lessons of ALS‐PDC – Environmental Factors in ALS Etiology
INTRODUCTION
KOCH’S POSTULATES IN THE SEARCH OF ETIOLOGICAL ALS FACTORS
NEUROLOGICAL DISEASE CLUSTERS
THE NATURAL HISTORY OF ALS‐PDC
INVESTIGATING ETIOLOGICAL FACTORS
IDENTIFIED CYCAD TOXIN/TOXICANTS
ALUMINUM AND IONIC ETIOLOGIES FOR ALS‐PDC
OTHER MOLECULES THAT MIGHT HAVE BEEN INVOLVED IN ALS‐PDC
A PUTATIVE VIRAL ETIOLOGY FOR ALS‐PDC ON GUAM AND ALS IN GENERAL
THE CONTINUING IMPORTANCE OF ALS‐PDC
SUMMARY AND CONCLUSIONS
ACKNOWLEDGMENTS
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 5: The Microbiome of ALS – Does It Start from the Gut?
INTRODUCTION
RECENT STUDIES
HOW COULD THE MICROBIOME CONTRIBUTE TO ALS?
MICROBIOME MODULATION AS A POTENTIAL THERAPEUTIC AVENUE
CONCLUSION
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 6: Protein Aggregation in Amyotrophic Lateral Sclerosis
INTRODUCTION
PATHOLOGICAL PROTEIN INCLUSIONS ASSOCIATED WITH ALS
CONSEQUENCES OF PROTEIN AGGREGATION IN ALS
THE PRIMARY AGGREGATING PROTEINS IN ALS
PRION‐LIKE PROPAGATION OF PROTEIN AGGREGATION IN ALS
CONCLUSION
ACKNOWLEDGMENTS
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 7: Evidence for a Growing Involvement of Glia in Amyotrophic Lateral Sclerosis
INTRODUCTION
NON‐NEURONAL CELLS PLAY IMPORTANT ROLES IN NEURODEGENERATION INCLUDING IN ALS
GLIAL ACTIVATION IN ALS MODELS
GLIAL INCLUSION FORMATION IN ALS
THE ROLE OF GLIAL CELLS IN SOD1 PATHOLOGY MIGHT BE DIFFERENT FROM OTHER FORMS OF ALS
CONCLUSION
ACKNOWLEDGMENTS
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 8: Animal Models of ALS – Current and Future Perspectives
INTRODUCTION
THE CLINICAL MANIFESTATIONS OF ALS
CURRENT AND EXPERIMENTAL PHARMACOLOGICAL INTERVENTIONS
CAUSATIVE FACTORS IN THE DEVELOPMENT OF ALS
ANIMAL MODELS OF ALS
FUTURE MODEL DEVELOPMENT
ACKNOWLEDGMENTS
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 9: Clinical Trials in ALS – Current Challenges and Strategies for Future Directions
INTRODUCTION
CHALLENGES IN ALS CLINICAL TRIALS
DISEASE HETEROGENEITY
LACK OF ESTABLISHED BIOMARKERS
LIMITATIONS OF CONVENTIONAL OUTCOME MEASURES
PHASE II TRIAL “PARADOX”
PATIENT RECRUITMENT AND RETENTION
ASSUMPTIONS FOR LEAD‐IN PHASES
NAVIGATING REGULATORY NUANCES
FUTURE DIRECTIONS
ADVANCES IN DISEASE UNDERSTANDING AND ASSESSMENT
NEW APPROACHES TO TRIAL DESIGN
EDUCATION
PEOPLE MAKE OR BREAK A TRIAL
ACKNOWLEDGMENTS
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
CHAPTER 10: Future Priorities and Directions in ALS Research and Treatment
INTRODUCTION
ETIOLOGICAL HETEROGENEITY OF ALS
ALS RISK FACTORS
CELLULAR DYSFUNCTION IN ALS
ALS AS A “TREATABLE” DISEASE
THE IMPORTANCE OF EFFECTIVE BIOMARKERS
FUTURE THERAPEUTIC AVENUES FOR A HETEROGENEOUS DISEASE
ONGOING CLINICAL TRIALS USING CuATSM
CONCLUSIONS AND THE ROAD FORWARD IN ALS RESEARCH AND TREATMENT
CONFLICT OF INTEREST
COPYRIGHT AND PERMISSION STATEMENT
REFERENCES
Index
End User License Agreement

People also search for Spectrums of Amyotrophic Lateral Sclerosis Heterogeneity Pathogenesis and Therapeutic Directions 1st:

spectrums of amyotrophic
    
als spectrum disease
    
als spectrum
    
characteristics of amyotrophic lateral sclerosis
    
amyotrophic-lateral-sclerosis